Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOVER60: Cabotegravir + Rilpivirine in HIV-1 Patients ≥ 60 Years
NCT06646562Phase 4Active, not recruiting
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cabotegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Fundación para la Formación e Investigación Sanitaria. Started Mar 2025; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06646562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646562.